Targeted SSTR (somatostatin receptor) radionuclide drug conjugates are a class of therapeutic agents designed for the targeted treatment of neuroendocrine tumors.This targeted delivery mechanism allows for the precise administration of radiation directly to tumor sites, effectively killing cancer cells while minimizing damage to surrounding healthy tissues.
The global Targeted SSTR Radionuclide Drug Conjugates market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
The market for targeted SSTR (somatostatin receptor) radionuclide drug conjugates is experiencing robust growth, largely driven by the rising incidence of neuroendocrine tumors (NETs) and increasing awareness of these malignancies. As diagnostic techniques improve and more patients are diagnosed with NETs, there is a growing demand for effective and targeted treatment options. This shift towards precision medicine emphasizes therapies that can specifically target cancer cells while minimizing impact on healthy tissue, making SSTR-targeted therapies increasingly appealing.
Recent clinical advancements, particularly the approval of therapies like ^177Lu-DOTATATE, have demonstrated significant efficacy in treating advanced NETs, leading to improved patient outcomes. The success of these therapies has prompted pharmaceutical companies to invest heavily in research and development, resulting in a pipeline of new SSTR-targeted radionuclide products. Ongoing clinical trials are exploring various combinations and delivery methods to enhance effectiveness, further fueling market interest and competition.
Additionally, the integration of targeted therapies into comprehensive cancer care is shaping the SSTR radionuclide market. Healthcare providers are increasingly adopting multidisciplinary approaches that combine different treatment modalities, positioning SSTR-targeted therapies as essential components of holistic cancer management. As clinicians and patients become more informed about the benefits of these advanced treatment options, the adoption of SSTR radionuclide drug conjugates is expected to rise, driving market growth in the coming years.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Targeted SSTR Radionuclide Drug Conjugates, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted SSTR Radionuclide Drug Conjugates.
The Targeted SSTR Radionuclide Drug Conjugates market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Targeted SSTR Radionuclide Drug Conjugates market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted SSTR Radionuclide Drug Conjugates manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Novartis
RadioMedix
Curium Pharma
ITM Radiopharma
Grand Pharmaceutical
Segment by Type
Diagnostic
Therapeutic
Segment by Application
Hospital
Specialist Clinic
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Targeted SSTR Radionuclide Drug Conjugates manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Targeted SSTR Radionuclide Drug Conjugates in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Overview
1.1 Product Definition
1.2 Targeted SSTR Radionuclide Drug Conjugates by Type
1.2.1 Global Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Diagnostic
1.2.3 Therapeutic
1.3 Targeted SSTR Radionuclide Drug Conjugates by Application
1.3.1 Global Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Specialist Clinic
1.3.4 Other
1.4 Global Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Targeted SSTR Radionuclide Drug Conjugates Revenue 2019-2030
1.4.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales 2019-2030
1.4.3 Global Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Competition by Manufacturers
2.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Targeted SSTR Radionuclide Drug Conjugates Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Targeted SSTR Radionuclide Drug Conjugates, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Targeted SSTR Radionuclide Drug Conjugates, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Targeted SSTR Radionuclide Drug Conjugates, Product Type & Application
2.7 Global Key Manufacturers of Targeted SSTR Radionuclide Drug Conjugates, Date of Enter into This Industry
2.8 Global Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Competitive Situation and Trends
2.8.1 Global Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest Targeted SSTR Radionuclide Drug Conjugates Players 麻豆原创 Share by Revenue
2.8.3 Global Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Scenario by Region
3.1 Global Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Region: 2019-2030
3.2.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Region: 2019-2024
3.2.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Region: 2025-2030
3.3 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Region: 2019-2030
3.3.1 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Region: 2019-2024
3.3.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Region: 2025-2030
3.4 North America Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Facts & Figures by Country
3.4.1 North America Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2019-2030)
3.4.3 North America Targeted SSTR Radionuclide Drug Conjugates Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Facts & Figures by Country
3.5.1 Europe Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2019-2030)
3.5.3 Europe Targeted SSTR Radionuclide Drug Conjugates Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Targeted SSTR Radionuclide Drug Conjugates Sales by Region (2019-2030)
3.6.3 Asia Pacific Targeted SSTR Radionuclide Drug Conjugates Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2019-2030)
3.7.3 Latin America Targeted SSTR Radionuclide Drug Conjugates Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2019-2030)
3.8.3 Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Type (2019-2030)
4.1.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Type (2019-2024)
4.1.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Type (2025-2030)
4.1.3 Global Targeted SSTR Radionuclide Drug Conjugates Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Type (2019-2030)
4.2.1 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Type (2019-2024)
4.2.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Type (2025-2030)
4.2.3 Global Targeted SSTR Radionuclide Drug Conjugates Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Targeted SSTR Radionuclide Drug Conjugates Price by Type (2019-2030)
5 Segment by Application
5.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Application (2019-2030)
5.1.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Application (2019-2024)
5.1.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Application (2025-2030)
5.1.3 Global Targeted SSTR Radionuclide Drug Conjugates Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Application (2019-2030)
5.2.1 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Application (2019-2024)
5.2.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Application (2025-2030)
5.2.3 Global Targeted SSTR Radionuclide Drug Conjugates Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Targeted SSTR Radionuclide Drug Conjugates Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Targeted SSTR Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 RadioMedix
6.2.1 RadioMedix Company Information
6.2.2 RadioMedix Description and Business Overview
6.2.3 RadioMedix Targeted SSTR Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.2.4 RadioMedix Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
6.2.5 RadioMedix Recent Developments/Updates
6.3 Curium Pharma
6.3.1 Curium Pharma Company Information
6.3.2 Curium Pharma Description and Business Overview
6.3.3 Curium Pharma Targeted SSTR Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Curium Pharma Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
6.3.5 Curium Pharma Recent Developments/Updates
6.4 ITM Radiopharma
6.4.1 ITM Radiopharma Company Information
6.4.2 ITM Radiopharma Description and Business Overview
6.4.3 ITM Radiopharma Targeted SSTR Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.4.4 ITM Radiopharma Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
6.4.5 ITM Radiopharma Recent Developments/Updates
6.5 Grand Pharmaceutical
6.5.1 Grand Pharmaceutical Company Information
6.5.2 Grand Pharmaceutical Description and Business Overview
6.5.3 Grand Pharmaceutical Targeted SSTR Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Grand Pharmaceutical Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
6.5.5 Grand Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Targeted SSTR Radionuclide Drug Conjugates Industry Chain Analysis
7.2 Targeted SSTR Radionuclide Drug Conjugates Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Targeted SSTR Radionuclide Drug Conjugates Production Mode & Process
7.4 Targeted SSTR Radionuclide Drug Conjugates Sales and 麻豆原创ing
7.4.1 Targeted SSTR Radionuclide Drug Conjugates Sales Channels
7.4.2 Targeted SSTR Radionuclide Drug Conjugates Distributors
7.5 Targeted SSTR Radionuclide Drug Conjugates Customers
8 Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Dynamics
8.1 Targeted SSTR Radionuclide Drug Conjugates Industry Trends
8.2 Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Drivers
8.3 Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Challenges
8.4 Targeted SSTR Radionuclide Drug Conjugates 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Novartis
RadioMedix
Curium Pharma
ITM Radiopharma
Grand Pharmaceutical
听
听
*If Applicable.